Literature DB >> 9630042

Cholelithiasis following Escherichia coli O157:H7-associated hemolytic uremic syndrome.

J R Brandt1, M W Joseph, L S Fouser, P I Tarr, I Zelikovic, R A McDonald, E D Avner, N G McAfee, S L Watkins.   

Abstract

Sequelae of Escherichia coli O157:H7-associated hemolytic uremic syndrome (HUS) 2-3 years following an outbreak in Washington State have been prospectively studied to identify predictors of adverse sequelae. Logistic regression analysis was used to examine associations between findings in the acute course and long-term renal and gastrointestinal outcomes. Twenty-one percent of patients had gastrointestinal sequelae, which included cholelithiasis resulting in cholecystectomy (3/29), persistent pancreatitis (2/29), late colon stricture (1/29), and/or glucose intolerance (1/29). Logistic regression analysis found long-term gastrointestinal sequelae were higher in patients who, during HUS, had hypertension [odds ratio (OR) = 21.2, 95% confidence interval (CI) = 1.9-164.4, P = 0.01] or gastrointestinal complications (OR = 21.2, 95% CI = 1.9-164.4, P = 0.01). Renal sequelae were seen in 35% of patients. One patient (4%) had persistent hypertension and 9 (31%) had minor urinary findings (hematuria or proteinuria). Thrombocytopenia lasting longer than 10 days during the acute illness was associated with a risk for subsequent renal sequelae (OR = 15.0, 95% CI = 1.98-1,703.0, P = 0.009). We conclude a high incidence of gastrointestinal sequelae, especially cholelithiasis presenting long after the acute illness, may be seen with HUS. The short follow-up period may underestimate the extent and severity of eventual renal sequelae.

Entities:  

Mesh:

Year:  1998        PMID: 9630042     DOI: 10.1007/s004670050442

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  7 in total

1.  Clinical surveillance of thrombotic microangiopathies in Scotland, 2003-2005.

Authors:  K G J Pollock; D Young; T J Beattie; W T A Todd
Journal:  Epidemiol Infect       Date:  2007-03-05       Impact factor: 2.451

Review 2.  Guidelines for the management and investigation of hemolytic uremic syndrome.

Authors:  Takashi Igarashi; Shuichi Ito; Mayumi Sako; Akihiko Saitoh; Hiroshi Hataya; Masashi Mizuguchi; Tsuneo Morishima; Kenji Ohnishi; Naohisa Kawamura; Hirotsugu Kitayama; Akira Ashida; Shinya Kaname; Hiromichi Taneichi; Julian Tang; Makoto Ohnishi
Journal:  Clin Exp Nephrol       Date:  2014-08       Impact factor: 2.801

Review 3.  Haemolytic uraemic syndrome.

Authors:  W L Robson
Journal:  Paediatr Drugs       Date:  2000 Jul-Aug       Impact factor: 3.022

4.  Prevalence of Escherichia coli O157:H7 in gallbladders of beef cattle.

Authors:  S Reinstein; J T Fox; X Shi; T G Nagaraja
Journal:  Appl Environ Microbiol       Date:  2006-12-08       Impact factor: 4.792

5.  Cholelithiasis associated with haemolytic-uraemic syndrome.

Authors:  Deepak Kejariwal
Journal:  World J Gastroenterol       Date:  2006-04-14       Impact factor: 5.742

Review 6.  Long-term outcomes of Shiga toxin hemolytic uremic syndrome.

Authors:  Joann M Spinale; Rebecca L Ruebner; Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2013-01-04       Impact factor: 3.714

7.  Hemolytic uremic syndrome (HUS)--incidence and etiologies at a regional Children's Hospital in 2001-2006.

Authors:  R J Pomajzl; M Varman; A Holst; A Chen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-08-16       Impact factor: 3.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.